Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset, autosomal dominant familial Parkinson's disease (PD) and also contribute to idiopathic PD. LRRK2 mutations represent the most common cause of PD with clinical and neurochemical features that are largely indistinguishable from idiopathic disease. Currently, transgenic mice expressing wild-type or disease-causing mutants of LRRK2 have failed to produce overt neurodegeneration, although abnormalities in nigrostriatal dopaminergic neurotransmission have been observed. Here, we describe the development and characterization of transgenic mice expressing human LRRK2 bearing the familial PD mutations, R1441C and G2019S. Our study demonstrates that expression of G2019S mutant LRRK2 induces the degeneration of nigrostriatal pathway dopaminergic neurons in an age-dependent manner. In addition, we observe autophagic and mitochondrial abnormalities in the brains of aged G2019S LRRK2 mice and markedly reduced neurite complexity of cultured dopaminergic neurons. These new LRRK2 transgenic mice will provide important tools for understanding the mechanism(s) through which familial mutations precipitate neuronal degeneration and PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 HPLC analysis of dopamine and its metabolites in G2019S LRRK2 transgenic mice. A–D, Levels of (A) dopamine (DA) and its metabolites, (B) DOPAC and (C) HVA, and (D) dopamine turnover ([DOPAC+HVA]/DA) in the striatum, olfactory bulb and cerebral cortex of 14–15 month-old G2019S LRRK2 TG mice (line 340) and their NTG littermates by HPLC analysis (n = 8/genotype). Bars present the mean ± SEM. *P<0.05 or **P<0.005 comparing TG with NTG as indicated.](https://figures.cochat.ai/paper-figures/2d21c616818941c89c421afafe071ad7/dopaminergic-neuronal-loss-reduced-neurite-complexity-and-autophagic-figure-4.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dysregulated autophagy has also been associated with the expression of dominant mutants of LRRK2 (leucine‐rich repeat kinase 2) (Ramonet et al, 2011), the most common cause of familial PD.”
From Autophagy in major human diseases (2021) · cites this paper as Ramonet et al, 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005 · cited 2×
“LRRK2-linked PD is characterized by the degeneration of substantia nigra dopaminergic neurons and gliosis together with heterogeneous protein inclusion pathology [3,10].”
BackgroundCloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
OPA1 Controls Apoptotic Cristae Remodeling Independently from Mitochondrial Fusion
Frezza, C., Cipolat, S., Martins de Brito, O., Micaroni, M., Beznoussenko, G. V., Rudka, T., Bartoli, D., Polishuck, R. S., Danial, N. N., De Strooper, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.025 · Cited by 1,673 · cited 1×
“area was determined for LRRK2 transgenic (TG) and non-transgenic (NTG) mice. Mitochondria were subclassified as either morphologically normal (class I), damaged (class II) or abnormally condensed/aggregated based upon previously established criteria (”
Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425 · cited 1×
“-linked families, including the R1441C/G/H, Y1699C, G2019S and I2020T variants”
BackgroundParkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228 · cited 1×
“1-LRRK2-Myc-His vector [18] was previously modified to introduce a 59 Kozak sequence and 39 stop codon (TAA) between flanking NheI sites.”
Self-citationNew stereological methods for counting neurons
West, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90112-o · Cited by 940 · cited 1×
“Unbiased stereological methodology was employed as described previously [55,56] to count TH+ and Nissl+ neurons in the left and right pars compacta region of every fourth section throughout the ventral midbrain.”
MethodA common LRRK2 mutation in idiopathic Parkinson's disease
Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S., Jain, S., Singleton, A., Lees, A. J., Shaw, K., Bhatia, K. P., Bonifati, V., Quinn, N. P., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17830-1 · Cited by 774 · cited 1×
“. Of these, G2019S is the most common variant that uniquely contributes to both familial and sporadic PD”
BackgroundKinase activity is required for the toxic effects of mutant LRRK2/dardarin
Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.001 · Cited by 671 · cited 1×
“LRRK2-induced neuronal toxicity in vitro in a GTP-binding- and kinase-dependent manner [13,19-22], suggesting a gain-of-function mechanism for familial mutations.”
BackgroundLRRK2 G2019S as a Cause of Parkinson's Disease in Ashkenazi Jews
Ozelius, L. J., Senthil, G., Saunders-Pullman, R., Ohmann, E., Deligtisch, A., Tagliati, M., Hunt, A. L., Klein, C., Henick, B., Hailpern, S. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmc055509 · Cited by 665
Cited by
Autophagy in major human diseases
Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585
Exner, N., Lutz, A. K., Haass, C., & Winklhofer, K. F. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.170 · Cited by 642
“Mitochondrial pathology has been observed in aged G2019S LRRK2 transgenic mice (Ramonet et al , 2011), and the expression of this mutant aggravates mitochondrial alterations in inducible A53T a - synuclein transgenic mice (Lin et al , 2009).”
Interplay of LRRK2 with chaperone-mediated autophagy
Orenstein, S. J., Kuo, S.-H., Tasset, I., Arias, E., Koga, H., Fernandez-Carasa, I., Cortes, E., Honig, L. S., Dauer, W., Consiglio, A., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3350 · Cited by 588
Parkinson’s disease: animal models and dopaminergic cell vulnerability
Blesa, J., & Przedborski, S. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00155 · Cited by 480
“Furthermore, no alteration in striatal DA levels or locomotor activity could be detected in older G2019S LRRK2 mice (Ramonet et al., 2011; Chen et al., 2012).”
BackgroundExcitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration
Verma, M., Lizama, B. N., & Chu, C. T. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-021-00278-7 · Cited by 451
Sarkar, S. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130134 · Cited by 370
Beilina, A., Rudenko, I. N., Kaganovich, A., Civiero, L., Chau, H., Kalia, S. K., Kalia, L. V., Lobbestael, E., Chia, R., Ndukwe, K., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318306111 · Cited by 348
“This effect is presumably related to the known function of LRRK2 in autophagy (18, 24, 33, 37, 38) but can be tied mechanistically to disruption of TGN.”
Sheng, Z., Zhang, S., Bustos, D., Kleinheinz, T., Le Pichon, C. E., Dominguez, S. L., Solanoy, H. O., Drummond, J., Zhang, X., Ding, X., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004485 · Cited by 353
Review: The role of vitamin D in nervous system health and disease
DeLuca, G. C., Kimball, S. M., Kolasinski, J., Ramagopalan, S. V., & Ebers, G. C. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12020 · Cited by 326
Henderson, M. X., Cornblath, E. J., Darwich, A., Zhang, B., Brown, H., Gathagan, R. J., Sandler, R. M., Bassett, D. S., Trojanowski, J. Q., & Lee, V. M. Y. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0457-5 · Cited by 310
Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP
Gómez-Suaga, P., Luzón-Toro, B., Churamani, D., Zhang, L., Bloor-Young, D., Patel, S., Woodman, P. G., Churchill, G. C., & Hilfiker, S. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr481 · Cited by 312
“In addition, transgenic mice expressing G2019S-mutant LRRK2 display progressive age-dependent degeneration of dopaminergic neurons in vivo, accompanied by the accumulation of autophagic structures (14).”
BackgroundFriedman, L. G., Lachenmayer, M. L., Wang, J., He, L., Poulose, S. M., Komatsu, M., Holstein, G. R., & Yue, Z. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5809-11.2012 · Cited by 303
“Several reports have shown that autophagic flux is impeded by familial LRRK2 mutations and indicates a role for LRRK2 in autophagy regulation (Plowey et al., 2008; AlegreAbarrategui et al., 2009; Ramonet et al., 2011).”
BackgroundNeuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease
Taylor, J. M., Main, B. S., & Crack, P. J. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.016 · Cited by 303
“In contrast, progressive nigro-striatal degeneration has been reported in human G2109S-LRRK2 mice (Ramonet et al., 2011).”
BackgroundMicroglial phenotypes in Parkinson’s disease and animal models of the disease
Joers, V., Tansey, M. G., Mulas, G., & Carta, A. R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.006 · Cited by 285
“Of note, one study reported an agedependent partial loss of nigral neurons and damage to the nigrostriatal system in mice carrying the G2019S LRRK2 mutation (Ramonet et al., 2011).”
BackgroundParkinson's disease, insulin resistance and novel agents of neuroprotection
Aviles-Olmos, I., Limousin, P., Lees, A., & Foltynie, T. (2013) · Brain · doi:10.1093/brain/aws009 · Cited by 283
“DJ-1 has been shown to associate with the mitochondrial Bcl-XL, an anti-apoptotic protein (Ren et al., 2011).”
BackgroundLRRK2 levels in immune cells are increased in Parkinson’s disease
Cook, D. A., Kannarkat, G. T., Cintron, A. F., Butkovich, L. M., Fraser, K. B., Chang, J., Grigoryan, N., Factor, S. A., West, A. B., Boss, J. M., et al. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-017-0010-8 · Cited by 279
Retrograde Axonal Degeneration in Parkinson Disease
Tagliaferro, P., & Burke, R. E. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-150769 · Cited by 272
“In another LRRK2 transgenic mouse model expressing the G2019S mutant, Ramonet and collaborators identified vacuoles with multiple membranes resembling autophagosomes within regions enriched in axons and synapses and clusters of mitochondria, reminiscent of mitochondria undergoing autophagocytosis, within neuronal soma…”
BackgroundProgressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice
Yue, M., Hinkle, K. M., Davies, P., Trushina, E., Fiesel, F. C., Christenson, T. A., Schroeder, A. S., Zhang, L., Bowles, E., Behrouz, B., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.02.031 · Cited by 281
Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease
Gan-Or, Z., Dion, P. A., & Rouleau, G. A. (2015) · Autophagy · doi:10.1080/15548627.2015.1067364 · Cited by 260
Programmed Cell Death in Parkinson's Disease
Venderova, K., & Park, D. S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009365 · Cited by 247
“Furthermore, PD genes LRRK2 (Plowey et al. 2008; Alegre-Abarrategui et al. 2009; Alegre-Abarrategui and Wade-Martins 2009; Tong et al. 2010; Hakimi et al. 2011; Ramonet et al. 2011; Gomez-Suaga et al. 2012), DJ-1 (Gonzalez-Polo et al. 2009; Irrcher et al. 2010; Krebiehl et al. 2010; Ren et al. 2010; McCoy and Cookson…”
InfluentialEvaluation of Models of Parkinson's Disease
Jagmag, S. A., Tripathi, N., Shukla, S. D., Maiti, S., & Khurana, S. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00503 · Cited by 226
Su, Y.-C., & Qi, X. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt301 · Cited by 222
Autophagy in Neurodegenerative Diseases: A Hunter for Aggregates
Park, H., Kang, J.-H., & Lee, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093369 · Cited by 207
Dovonou, A., Bolduc, C., Soto Linan, V., Gora, C., Peralta III, M. R., & Lévesque, M. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00368-8 · Cited by 184
“neuroinflammation, as well as autophagic and mitochondrial abnormalities are also present despite the absence of synucleinopathies [158, 159].”
BackgroundAnimal models of Parkinson's disease
Jackson-Lewis, V., Blesa, J., & Przedborski, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70057-8 · Cited by 191
Modelling of Parkinson's disease in mice
Chesselet, M.-F., & Richter, F. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70227-7 · Cited by 192
Mutant LRRK2 Elicits Calcium Imbalance and Depletion of Dendritic Mitochondria in Neurons
Cherra, S. J., Steer, E., Gusdon, A. M., Kiselyov, K., & Chu, C. T. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.10.027 · Cited by 190
The role of autophagy in modulation of neuroinflammation in microglia
Su, P., Zhang, J., Wang, D., Zhao, F., Cao, Z., Aschner, M., & Luo, W. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.01.035 · Cited by 184
LRRK2 at the interface of autophagosomes, endosomes and lysosomes
Roosen, D. A., & Cookson, M. R. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0140-1 · Cited by 185
“Finally, in vivo, mice carrying the G2019S mutation show an accumulation of autophagic vacuoles in the cerebral cortex, as do R1441C LRRK2 transgenic mice [69].”
Genetic predispositions of Parkinson’s disease revealed in patient-derived brain cells
Tran, J., Anastacio, H., & Bardy, C. (2020) · npj Parkinson's Disease · doi:10.1038/s41531-020-0110-8 · Cited by 176
Cellular processes associated with LRRK 2 function and dysfunction
Wallings, R., Manzoni, C., & Bandopadhyay, R. (2015) · The FEBS Journal · doi:10.1111/febs.13305 · Cited by 174
Genetics and genomics of Parkinson’s disease
Lin, M. K., & Farrer, M. J. (2014) · Genome Medicine · doi:10.1186/gm566 · Cited by 179
“G2019S transgenic mice [131].”
Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies
Bezard, E., Yue, Z., Kirik, D., & Spillantini, M. G. (2013) · Movement Disorders · doi:10.1002/mds.25108 · Cited by 173
“A most recent study reports a new Tg line expressing LRRK2-G2019S that exhibits late-onset, modest loss of DA neurons at the SNpc.(90) However, it is unclear, at this stage, whether the locomotor abnormality and neuronal loss are relevant to the etiology of PD.”
BackgroundLRRK2 regulation of immune-pathways and inflammatory disease
Wallings, R. L., & Tansey, M. G. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180463 · Cited by 173
Review: Axon pathology in age‐related neurodegenerative disorders
Adalbert, R., & Coleman, M. P. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01308.x · Cited by 165
Boecker, C. A., Goldsmith, J., Dou, D., Cajka, G. G., & Holzbaur, E. L. F. (2021) · Current Biology · doi:10.1016/j.cub.2021.02.061 · Cited by 165
The cell biology of Parkinson’s disease
Panicker, N., Ge, P., Dawson, V. L., & Dawson, T. M. (2021) · Journal of Cell Biology · doi:10.1083/jcb.202012095 · Cited by 159
“However, G2019S LRRK2 transgenic mice do show DA neuron loss (Chen et al., 2012; Ramonet et al., 2011).”
BackgroundSelf-citationRamonet, D., Podhajska, A., Stafa, K., Sonnay, S., Trancikova, A., Tsika, E., Pletnikova, O., Troncoso, J. C., Glauser, L., & Moore, D. J. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr606 · Cited by 161
Self-citationParkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration
Tsika, E., Glauser, L., Moser, R., Fiser, A., Daniel, G., Sheerin, U.-M., Lees, A., Troncoso, J. C., Lewis, P. A., Bandopadhyay, R., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu178 · Cited by 159
“Unbiased stereological estimation of the number of dopaminergic neurons was performed using the optical fractionator probe of the StereoInvestigator software (MicroBrightField Biosciences), as described (37,38).”
BackgroundMethodSelf-citationGlial phagocytic clearance in Parkinson’s disease
Tremblay, M.-E., Cookson, M. R., & Civiero, L. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0314-8 · Cited by 152
“oles within regions enriched in axons and/or synapses have been reported in transgenic mice overexpressing the G2019S LRRK2 mutation [151].”
BackgroundInhibition of LRRK2 kinase activity stimulates macroautophagy
Manzoni, C., Mamais, A., Dihanich, S., Abeti, R., Soutar, M. P. M., Plun-Favreau, H., Giunti, P., Tooze, S. A., Bandopadhyay, R., & Lewis, P. A. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.07.020 · Cited by 151
Autophagy in axonal and dendritic degeneration
Yang, Y., Coleman, M., Zhang, L., Zheng, X., & Yue, Z. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.04.001 · Cited by 147
“In G2019S LRRK2 transgenic mice, an animal model for PD, autophagosomes appear in synaptic terminal in cerebral cortex at advanced age (17–18 months) [57].”
BackgroundGómez-Suaga, P., Rivero-Ríos, P., Fdez, E., Blanca Ramírez, M., Ferrer, I., Aiastui, A., López De Munain, A., & Hilfiker, S. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu395 · Cited by 140
Brain Penetrant LRRK2 Inhibitor
Choi, H. G., Zhang, J., Deng, X., Hatcher, J. M., Patricelli, M. P., Zhao, Z., Alessi, D. R., & Gray, N. S. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300123a · Cited by 132
“LRRK2: Autophagy and Lysosomal Activity”
Madureira, M., Connor-Robson, N., & Wade-Martins, R. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00498 · Cited by 137
Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo
Kozina, E., Sadasivan, S., Jiao, Y., Dou, Y., Ma, Z., Tan, H., Kodali, K., Shaw, T., Peng, J., & Smeyne, R. J. (2018) · Brain · doi:10.1093/brain/awy077 · Cited by 140
Stafa, K., Tsika, E., Moser, R., Musso, A., Glauser, L., Jones, A., Biskup, S., Xiong, Y., Bandopadhyay, R., Dawson, V. L., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt600 · Cited by 134
“LRRK2robustly regulatesneuronalprocesscomplexity inprimary cultures with the overexpression of PD-associated mutants leading to reduced neurite length and branching and oppositely deletion or silencing of LRRK2 enhancing neurite complexity (15,21,29,32).”
BackgroundSelf-citationModels of α-synuclein aggregation in Parkinson’s disease
Giráldez-Pérez, R. M., Antolín-Vallespín, M., Muñoz, M. D., & Sánchez-Capelo, A. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0176-9 · Cited by 132
“Mice overexpressing the G2019S mutation in LRRK2 do not reproduce any obvious gross neuropathological phenotypes nor is α-syn aggregation observed, although this LRRK2 mutation may accelerate the pathogenic phenotype of A53T α-syn mice [136-138].”
BackgroundVan Laar, V. S., & Berman, S. B. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.015 · Cited by 131
LRRK2 and mitochondria: Recent advances and current views
Singh, A., Zhi, L., & Zhang, H. (2019) · Brain Research · doi:10.1016/j.brainres.2018.06.010 · Cited by 130
Stafa, K., Trancikova, A., Webber, P. J., Glauser, L., West, A. B., & Moore, D. J. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002526 · Cited by 127
“In the brains of transgenic mice, the expression of human R1441C and G2019S LRRK2 leads to the abnormal accumulation of autophagic vacuoles [35].”
BackgroundSelf-citationMatikainen-Ankney, B. A., Kezunovic, N., Mesias, R. E., Tian, Y., Williams, F. M., Huntley, G. W., & Benson, D. L. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.3314-15.2016 · Cited by 139
“Several laboratories have shown that overexpression of LRRK2–G2019S can reduce neurite growth (MacLeod et al., 2006; Parisiadou et al., 2009; Dächsel et al., 2010; Ramonet et al., 2011; Winner et al., 2011; Sepulveda et al., 2013).”
BackgroundAnimal Models of Parkinson's Disease: Vertebrate Genetics
Lee, Y., Dawson, V. L., & Dawson, T. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009324 · Cited by 132
“, conventional, BAC transgenic, mutant LRRK2 KI, and tet-inducible transgenic), only one of the LRRK2 models reproduces age-dependent nigral DA neuron death (Ramonet et al. 2011).”
BackgroundSelf-citationVerma, M., Callio, J., Otero, P. A., Sekler, I., Wills, Z. P., & Chu, C. T. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3791-16.2017 · Cited by 128
Autophagy in health and disease: From molecular mechanisms to therapeutic target
Lu, G. X., Wang, Y., Shi, Y. P., Zhang, Z., Huang, C., He, W., Wang, C., & Shen, H. (2022) · MedComm · doi:10.1002/mco2.150 · Cited by 149
Beccano-Kelly, D. A., Kuhlmann, N., Tatarnikov, I., Volta, M., Munsie, L. N., Chou, P., Cao, L.-P., Han, H., Tapia, L., Farrer, M. J., et al. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00301 · Cited by 97
“Also, there is consensus from several studies that wild-type overexpression and mutant overexpression both result in shortened dendritic length (MacLeod et al., 2006; Parisiadou et al., 2009; Dachsel et al., 2010; Ramonet et al., 2011; Winner et al., 2011; Sepulveda et al., 2013).”
BackgroundKawakami, F., Yabata, T., Ohta, E., Maekawa, T., Shimada, N., Suzuki, M., Maruyama, H., Ichikawa, T., & Obata, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030834 · Cited by 123
“, i) neurite shortening due to G2019S-LRRK2 expression in differentiated SH-SY5Y cells [16,17], ii) shortened neurites of cultured neurons derived from G2019S-LRRK2 transgenic mice [18], and iii) markedly reduced neurite complexity of cultured dopaminergic neurons in the brains of aged G2019S-LRRK2 transgenic mice [19…”
BackgroundAnimal models of Parkinson's disease: An updated overview
Gubellini, P., & Kachidian, P. (2015) · Revue Neurologique · doi:10.1016/j.neurol.2015.07.011 · Cited by 148
The Interplay between Ca2+ Signaling Pathways and Neurodegeneration
Ureshino, R. P., Erustes, A. G., Bassani, T. B., Wachilewski, P., Guarache, G. C., Nascimento, A. C., Costa, A. J., Smaili, S. S., & da Silva Pereira, G. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236004 · Cited by 117
“The overexpression of an LRRK2 mutant in neuronal cells decreased neurite process length, along with a concomitant accumulation of autophagic structures [215,216].”
BackgroundParkinson’s disease: experimental models and reality
Jiang, P., & Dickson, D. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-017-1788-5 · Cited by 111
“Besides the changes of autophagic activity, some PD features, such as motor dysfunction, neuronal loss, dopamine depletion, and axonal degeneration have been observed in different LRRK2 models [108, 148, 164, 191]; however, none has αS pathology.”
Dynamic control of the dopamine transporter in neurotransmission and homeostasis
Bu, M., Farrer, M. J., & Khoshbouei, H. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00161-2 · Cited by 122
LRRK2 interacts with the vacuolar-type H+-ATPase pump a1 subunit to regulate lysosomal function
Wallings, R., Connor-Robson, N., & Wade-Martins, R. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz088 · Cited by 115
Dysregulation of autophagy and mitochondrial function in Parkinson’s disease
Wang, B., Abraham, N., Gao, G., & Yang, Q. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-016-0065-1 · Cited by 105
“Moreover, G2019S mutation increases autophagic vacuoles and shortens neurite length [74].”
BackgroundLee, J. H., Han, J.-H., Kim, H., Park, S. M., Joe, E.-H., & Jou, I. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0716-4 · Cited by 103
“toxic effect of LRRK2-GS on neurons [41, 65].”
LRRK2 and the Endolysosomal System in Parkinson’s Disease
Erb, M. L., & Moore, D. J. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202138 · Cited by 121
Self-citationTherapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease
Jasutkar, H. G., Oh, S. E., & Mouradian, M. M. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000133 · Cited by 111
“These include leucine-rich repeat kinase 2 (LRRK2) (Alegre-Abarrategui et al., 2009; Ramonet et al., 2011; Bravo-San Pedro et al., 2013; Soukup et al., 2016); glucocerebrosidase, which is a degradative enzyme within the lysosome and the most common genetic risk factor for PD (Neumann et al., 2009);…”
BackgroundNeural stem cells in Parkinson’s disease: a role for neurogenesis defects in onset and progression
Grand, J. N. L., González-Cano, L., Pavlou, M. A. S., & Schwamborn, J. C. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1774-1 · Cited by 112
“The LRRK2 protein may interact with the regulator of neurite outgrowth during embryonic neurogenesis, CRMP2 [77] and numerous studies have demonstrated that mutant LRRK2 overexpression decreases neurite length/outgrowth, while LRRK2 deficits result in an increase of neurite length and arborization [78–94].”
BackgroundThe associations between Parkinson’s disease and cancer: the plot thickens
Feng, D. D., Cai, W., & Chen, X. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0043-z · Cited by 103
“Consequences of the G2019S mutation include gain-of-function increase in LRRK2 protein kinase activity and ubiquitination [89], increased glutamatergic synapse activity and synaptic vesicle release [90], decreased levels of neurotrophic protein progranulin in microglia and fibroblasts [91], a protein linked to neurite…”
BackgroundVerma, M., Wills, Z. P., & Chu, C. T. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00523 · Cited by 108
“…of the dendritic arbor represents one of the most frequently reported phenotypes exhibited by neurons expressing disease-linked mutations in LRRK2 (MacLeod et al., 2006; Ramonet et al., 2011; Winner et al., 2011; Cherra et al., 2013; Reinhardt et al., 2013; Plowey et al., 2014; Verma et al., 2017).”
LRRK2, a puzzling protein: Insights into Parkinson's disease pathogenesis
Esteves, A. R., Swerdlow, R. H., & Cardoso, S. M. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.05.025 · Cited by 98
“Cultured dopamine neurons from these mice display markedly reduced neurite complexity (Ramonet et al., 2011).”
BackgroundParkinson's: A Disease of Aberrant Vesicle Trafficking
Singh, P. K., & Muqit, M. M. K. (2020) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100818-125512 · Cited by 96
“Additionally, transgenic mice expressing LRRK2 G2019S showed autophagic impairment in the aged brain (Ramonet et al. 2011).”
BackgroundLongo, F., Mercatelli, D., Novello, S., Arcuri, L., Brugnoli, A., Vincenzi, F., Russo, I., Berti, G., Mabrouk, O. S., Kennedy, R. T., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0426-8 · Cited by 97
“In mice where hG29019S [13, 64] or hR1441C [88] overexpression in SNc was achieved through the CMV/ PDGF promoter, an 18–50% reduction in the number of nigral DA cells was observed at old ages (16–21”
BackgroundLrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner
Shutinoski, B., Hakimi, M., Harmsen, I. E., Lunn, M., Rocha, J., Lengacher, N., Zhou, Y. Y., Khan, J., Nguyen, A., Hake-Volling, Q., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aas9292 · Cited by 96
Ho, D. H., Je, A. R., Lee, H., Son, I., Kweon, H.-S., Kim, H.-G., & Seol, W. (2018) · Experimental Neurobiology · doi:10.5607/en.2018.27.3.171 · Cited by 95
Helley, M., Pinnell, J. R., Sportelli, C., & Tieu, K. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00177 · Cited by 110
“Ultrastructural studies show an accumulation of condensed, disorganized and damaged mitochondria consistent with deficits in mitophagy and mitochondrial dynamics (Ramonet et al., 2011; Yue et al., 2015).”
BackgroundXiong, Y., Neifert, S., Karuppagounder, S. S., Liu, Q., Stankowski, J. N., Lee, B. D., Ko, H. S., Lee, Y., Grima, J. C., Mao, X., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712648115 · Cited by 97
Self-citationGenes associated with Parkinson's disease: regulation of autophagy and beyond
Beilina, A., & Cookson, M. R. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13266 · Cited by 93
“LRRK2 is also found in autophagic vesicles when expressed in cells or mouse models (Biskup et al. 2006; Plowey et al. 2008; Alegre-Abarrategui et al. 2009; Ramonet et al. 2011).”
BackgroundIslam, M. S., Nolte, H., Jacob, W., Ziegler, A. B., Pütz, S., Grosjean, Y., Szczepanowska, K., Trifunovic, A., Braun, T., Heumann, H., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw352 · Cited by 93
“Consistent with such a notion, the overexpression of R1441G LRRK2 in transgenic mice results in disturbed dopaminergic neurotransmission (75), whereas R1441C LRRK2 transgenic mice exhibit autophagic abnormalities (68).”
BackgroundSelf-citationMitochondrial Dysfunction in Genetic Animal Models of Parkinson's Disease
Trancikova, A. K., Tsika, E., & Moore, D. J. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4200 · Cited by 100
“Silencing of LRRK2 expression in primary neurons enhances the length and branching of neuronal processes (28, 107), whereas overexpression of human LRRK2 variants oppositely reduces neuritic complexity (107, 135, 148).”
InfluentialSelf-citationNeurodegenerative phenotypes in an A53T -synuclein transgenic mouse model are independent of LRRK2
Daher, J. P. L., Pletnikova, O., Biskup, S., Musso, A., Gellhaar, S., Galter, D., Troncoso, J. C., Lee, M. K., Dawson, T. M., Dawson, V. L., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds057 · Cited by 96
“WT, G2019S-LRRK2 and LRRK2-KO mice typically exhibit normal survival up to 24 months of age (data not shown), as reported previously (24,32).”
BackgroundMethodInfluentialSelf-citationMarker, D. F., Puccini, J. M., Mockus, T. E., Barbieri, J., Lu, S.-M., & Gelbard, H. A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-261 · Cited by 90
“LRRK2 kinase over-activity, specifically due to the LRRK2(G2019S) mutation, has been shown to decrease neurite outgrowth and complexity, in both in vitro and in vivo models [26,56-59].”
BackgroundIs LRRK2 the missing link between inflammatory bowel disease and Parkinson’s disease?
Herrick, M. K., & Tansey, M. G. (2021) · npj Parkinson's Disease · doi:10.1038/s41531-021-00170-1 · Cited by 91
Ness, D., Ren, Z., Gardai, S., Sharpnack, D., Johnson, V. J., Brennan, R. J., Brigham, E. F., & Olaharski, A. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066164 · Cited by 88
Manzoni, C., Mamais, A., Dihanich, S., McGoldrick, P., Devine, M. J., Zerle, J., Kara, E., Taanman, J.-W., Healy, D. G., Marti-Masso, J.-F., et al. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.10.159 · Cited by 81
Animal models of Parkinson’s disease: a guide to selecting the optimal model for your research
Lama, J., Buhidma, Y., Fletcher, E. J. R., & Duty, S. (2021) · Neuronal Signaling · doi:10.1042/ns20210026 · Cited by 102
Wang, C., Yang, T., Liang, M., Xie, J., & Song, N. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00265-y · Cited by 91
LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease?
O’Hara, D. M., Pawar, G., Kalia, S. K., & Kalia, L. V. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00577 · Cited by 85
Schwab, A. J., & Ebert, A. D. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.11.004 · Cited by 83
“Cultured dopaminergic neurons from human LRRK2-G2019S-expressing transgenic mice and patient-specific induced pluripotent stem cells (iPSCs) display shortened neurites and reduced neurite complexity (Ramonet et al., 2011; Cooper et al., 2012; Sánchez-Danés et al., 2012; Reinhardt et al., 2013).”
BackgroundModels of LRRK2-Associated Parkinson’s Disease
Xiong, Y., Dawson, T. M., & Dawson, V. L. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-49969-7_9 · Cited by 77
“Several transgenic techniques for LRRK2 related PD modeling in mice have been utilized, including conventional [65, 73, 69, 70], BAC transgenic [66–68], tet-inducible transgenic [60, 71] and mutant LRRK2 knock-in techniques [72, 58, 74, 75].”
BackgroundMethodSelf-citationMigheli, R., Del Giudice, M. G., Spissu, Y., Sanna, G., Xiong, Y., Dawson, T. M., Dawson, V. L., Galioto, M., Rocchitta, G., Biosa, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077198 · Cited by 82
“gy-lysosomal pathways [15,16] and immunoregulation [17].”
BackgroundSelf-citationDecreased sirtuin deacetylase activity in LRRK2 G2019S iPSC-derived dopaminergic neurons
Schwab, A. J., Sison, S. L., Meade, M. R., Broniowska, K. A., Corbett, J. A., & Ebert, A. D. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.10.010 · Cited by 80
“Therefore, disruption in stationary mitochondriamay explain the deficient neurite elongation and branching that we and others have observed in LRRK2 G2019S-expressing neurons (MacLeod et al., 2006; Plowey et al., 2008; Cherra et al., 2010; Ramonet et al., 2011; Cooper et al., 2012; Sanchez-Danes et al., 2012; Reinhard…”
BackgroundLeucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease
Lee, B. D., Dawson, V. L., & Dawson, T. M. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.04.001 · Cited by 95
“One exception is a transgenic model that shows modest late-age degeneration of DA neurons [43].”
BackgroundSelf-citationTsika, E., Kannan, M., Foo, C. S.-Y., Dikeman, D. A., Glauser, L., Gellhaar, S., Galter, D., Knott, G. W., Dawson, T. M., Dawson, V. L., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.027 · Cited by 93
Self-citationThe Neurobiology of LRRK2 and its Role in the Pathogenesis of Parkinson’s Disease
Rideout, H. J., & Stefanis, L. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1073-5 · Cited by 90
High LRRK2 Levels Fail to Induce or Exacerbate Neuronal Alpha-Synucleinopathy in Mouse Brain
Herzig, M. C., Bidinosti, M., Schweizer, T., Hafner, T., Stemmelen, C., Weiss, A., Danner, S., Vidotto, N., Stauffer, D., Barske, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036581 · Cited by 74
“Others have reported either changes [47,53,54] or no changes [51,55] in motor behaviors in mice overexpressing LRRK2(G2019S).”
BackgroundResultThe multi‐faceted role of mitochondria in the pathology of Parkinson’s disease
Trinh, D., Israwi, A. R., Arathoon, L. R., Gleave, J. A., & Nash, J. E. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15154 · Cited by 77
“In mice and cells over-expressing mutant LRRK2 G2019S, increased mitochondrial fragmentation is observed (Niu et al., 2012; Ramonet et al., 2011; Su & Qi, 2013; Wang et al., 2012); however, another study showed increased mitochondrial connectivity in fibroblasts from PD patient expressing the LRRK2…”
BackgroundConformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2
Schmidt, S. H., Weng, J.-H., Aoto, P. C., Boassa, D., Mathea, S., Silletti, S., Torres-Paris, C., Hu, J., Wallbott, M., Komives, E. A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2100844118 · Cited by 66
“This supports the hypothesis that the inert N-terminal scaffolding domains are not required for the filaments to form but instead are essential for protecting or shielding the catalytic domains to prevent them from docking onto MTs.”
BackgroundInfluentialPrimary Culture of Mouse Dopaminergic Neurons
Gaven, F., Marin, P., & Claeysen, S. (2014) · Journal of Visualized Experiments · doi:10.3791/51751 · Cited by 86
Nguyen, A. P. T., Tsika, E., Kelly, K., Levine, N., Chen, X., West, A. B., Boularand, S., Barneoud, P., & Moore, D. J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922184117 · Cited by 68
“nigra dopaminergic neurons was performed using the optical fractionator probe of the StereoInvestigator software (MicroBrightField Biosciences), as described (32, 35, 44).”
Self-citationChou, J.-S., Chen, C.-Y., Chen, Y.-L., Weng, Y.-H., Yeh, T.-H., Lu, C.-S., Chang, Y.-M., & Wang, H.-L. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.04.021 · Cited by 72
Metadata
- Authors
- Ramonet, D., Daher, J. P. L., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., Liu, Y., Swing, D. A., Beal, M. F., Troncoso, J. C., McCaffery, J. M., Jenkins, N. A., Copeland, N. G., Galter, D., Thomas, B., Lee, M. K., Dawson, T. M., Dawson, V. L., & Moore, D. J.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Johns Hopkins University (US)
- University of Minnesota (US)
- Cornell University (US)
- Karolinska Institutet (SE)
- National Cancer Institute (US)
- Corresponding author
- Dawson, Valina L.
- Moore, Darren J.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-04-06
- Volume
- 6
- Issue
- 4
- Pages
- e18568
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3071839
- OpenAlex
- W2166593844
- Cited by
- 405
- References
- 61
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 8 · 2023: 14 · 2022: 23 · 2021: 27 · 2020: 31 · 2019: 28 · 2018: 33 · 2017: 32 · 2016: 27 · 2015: 27 · 2014: 39 · 2013: 36 · 2012: 44
- FWCI
- 26.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- National Science Foundation
- National Parkinson Foundation
- American Parkinson Disease Association
- Johns Hopkins University
- École Polytechnique Fédérale de Lausanne
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (127478)
- Vetenskapsrådet
- Parkinson Schweiz
- National Institutes of Health
- Parkinsonfonden
- National Institute of Neurological Disorders and Stroke (R01NS060885, NS060885, NS03877, P50NS038377, NS062165, R21NS062165)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- LRRK2, G2019S mutation, familial Parkinson's disease, transgenic mouse model, dopaminergic neuron loss, nigrostriatal pathway, neurite complexity, autophagy, mitochondrial abnormalities, age-related neurodegeneration
- MeSH terms
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Animals, Autophagy, Behavior, Animal, Chromatography, High Pressure Liquid, Dopamine, Humans, Mesencephalon, Mice, Transgenic, Motor Activity, Organ Culture Techniques, Neurites, Protein Serine-Threonine Kinases, Amino Acid Substitution, Protein Transport, Mutant Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.